JPWO2020025659A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020025659A5 JPWO2020025659A5 JP2021529519A JP2021529519A JPWO2020025659A5 JP WO2020025659 A5 JPWO2020025659 A5 JP WO2020025659A5 JP 2021529519 A JP2021529519 A JP 2021529519A JP 2021529519 A JP2021529519 A JP 2021529519A JP WO2020025659 A5 JPWO2020025659 A5 JP WO2020025659A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- fusion protein
- acid sequence
- subunit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000037865 fusion proteins Human genes 0.000 claims description 111
- 108020001507 fusion proteins Proteins 0.000 claims description 111
- 150000001413 amino acids Chemical group 0.000 claims description 53
- 102000008096 B7-H1 Antigen Human genes 0.000 claims description 39
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 39
- 102000019298 Lipocalin Human genes 0.000 claims description 30
- 108050006654 Lipocalin Proteins 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 20
- 210000004881 tumor cell Anatomy 0.000 claims description 17
- 206010028980 Neoplasm Diseases 0.000 claims description 14
- 101001023833 Homo sapiens Neutrophil gelatinase-associated lipocalin Proteins 0.000 claims description 12
- 125000000539 amino acid group Chemical group 0.000 claims description 12
- 102000047202 human LCN2 Human genes 0.000 claims description 12
- 102000039446 nucleic acids Human genes 0.000 claims description 11
- 108020004707 nucleic acids Proteins 0.000 claims description 11
- 150000007523 nucleic acids Chemical class 0.000 claims description 11
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims description 10
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 10
- 229920001184 polypeptide Polymers 0.000 claims description 10
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 10
- 230000028327 secretion Effects 0.000 claims description 10
- 108060003951 Immunoglobulin Proteins 0.000 claims description 9
- 102000018358 immunoglobulin Human genes 0.000 claims description 9
- 230000005867 T cell response Effects 0.000 claims description 8
- 230000001939 inductive effect Effects 0.000 claims description 8
- 239000003145 cytotoxic factor Substances 0.000 claims description 7
- 239000000427 antigen Substances 0.000 claims description 6
- 102000036639 antigens Human genes 0.000 claims description 6
- 108091007433 antigens Proteins 0.000 claims description 6
- 210000004027 cell Anatomy 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 5
- 230000035772 mutation Effects 0.000 claims description 5
- 102000001398 Granzyme Human genes 0.000 claims description 4
- 108060005986 Granzyme Proteins 0.000 claims description 4
- 102000000588 Interleukin-2 Human genes 0.000 claims description 4
- 108010002350 Interleukin-2 Proteins 0.000 claims description 4
- 241000282567 Macaca fascicularis Species 0.000 claims description 4
- 210000004698 lymphocyte Anatomy 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 230000007783 downstream signaling Effects 0.000 claims description 3
- HKZAAJSTFUZYTO-LURJTMIESA-N (2s)-2-[[2-[[2-[[2-[(2-aminoacetyl)amino]acetyl]amino]acetyl]amino]acetyl]amino]-3-hydroxypropanoic acid Chemical compound NCC(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](CO)C(O)=O HKZAAJSTFUZYTO-LURJTMIESA-N 0.000 claims description 2
- 102000002627 4-1BB Ligand Human genes 0.000 claims description 2
- 108010082808 4-1BB Ligand Proteins 0.000 claims description 2
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 claims description 2
- 238000012286 ELISA Assay Methods 0.000 claims description 2
- 102100037850 Interferon gamma Human genes 0.000 claims description 2
- 108010074328 Interferon-gamma Proteins 0.000 claims description 2
- 102000004503 Perforin Human genes 0.000 claims description 2
- 108010056995 Perforin Proteins 0.000 claims description 2
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 claims description 2
- 229920000037 Polyproline Polymers 0.000 claims description 2
- 230000006052 T cell proliferation Effects 0.000 claims description 2
- 230000004913 activation Effects 0.000 claims description 2
- 230000001580 bacterial effect Effects 0.000 claims description 2
- 230000001419 dependent effect Effects 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 238000000684 flow cytometry Methods 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 229930192851 perforin Natural products 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- 108010026466 polyproline Proteins 0.000 claims description 2
- 230000035755 proliferation Effects 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 claims description 2
- 230000004044 response Effects 0.000 claims description 2
- 101000946124 Homo sapiens Lipocalin-1 Proteins 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 description 9
- 210000004602 germ cell Anatomy 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18186445 | 2018-07-31 | ||
| EP18186445.5 | 2018-07-31 | ||
| EP18204548 | 2018-11-06 | ||
| EP18204548.4 | 2018-11-06 | ||
| PCT/EP2019/070596 WO2020025659A1 (fr) | 2018-07-31 | 2019-07-31 | Nouvelle protéine de fusion spécifique à cd137 et pd-l1 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021533203A JP2021533203A (ja) | 2021-12-02 |
| JPWO2020025659A5 true JPWO2020025659A5 (fr) | 2022-07-28 |
| JP7482488B2 JP7482488B2 (ja) | 2024-05-14 |
Family
ID=67480227
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021529519A Active JP7482488B2 (ja) | 2018-07-31 | 2019-07-31 | Ｃｄ１３７とｐｄ－ｌ１に特異的な新規融合タンパク質 |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US20210363257A1 (fr) |
| EP (2) | EP4249064A3 (fr) |
| JP (1) | JP7482488B2 (fr) |
| KR (1) | KR20210040103A (fr) |
| CN (1) | CN112789292A (fr) |
| AU (1) | AU2019315703A1 (fr) |
| BR (1) | BR112020025263A2 (fr) |
| CA (1) | CA3100119A1 (fr) |
| CL (1) | CL2021000207A1 (fr) |
| CY (1) | CY1126148T1 (fr) |
| DK (1) | DK3830120T3 (fr) |
| ES (1) | ES2948717T3 (fr) |
| FI (1) | FI3830120T3 (fr) |
| HR (1) | HRP20230590T2 (fr) |
| HU (1) | HUE062320T2 (fr) |
| IL (1) | IL279541A (fr) |
| LT (1) | LT3830120T (fr) |
| MD (1) | MD3830120T3 (fr) |
| MX (1) | MX2021000401A (fr) |
| PH (1) | PH12021550001A1 (fr) |
| PL (1) | PL3830120T3 (fr) |
| RS (1) | RS64343B9 (fr) |
| SG (1) | SG11202100989UA (fr) |
| SI (1) | SI3830120T1 (fr) |
| TW (1) | TWI837156B (fr) |
| WO (1) | WO2020025659A1 (fr) |
| ZA (1) | ZA202100125B (fr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019388808A1 (en) * | 2018-11-29 | 2021-06-17 | Harbour Biomed Therapeutics Limited | Anti-PD-L1 antibody preparation |
| CN113939307A (zh) * | 2019-03-29 | 2022-01-14 | 皮里斯制药有限公司 | 脂质运载蛋白突变蛋白的吸入施用 |
| CN114555638B (zh) | 2019-10-11 | 2023-08-22 | 南京维立志博生物科技有限公司 | 结合4-1bb的抗体及其用途 |
| EP4161957A1 (fr) | 2020-06-05 | 2023-04-12 | Pieris Pharmaceuticals GmbH | Immunomodulateur multimère ciblant 4-1bb |
| KR20230129271A (ko) * | 2021-01-08 | 2023-09-07 | 베이징 한미 파마슈티컬 컴퍼니 리미티드 | 항pd-l1/항4-1bb 천연항체 구조 형태의 헤테로다이머이중특이성 항체 및 그 제조방법 |
| CN115521379B (zh) * | 2021-07-16 | 2023-12-22 | 南京吉盛澳玛生物医药有限公司 | Pd-1抗体及其用途 |
| CN114736303A (zh) * | 2022-03-17 | 2022-07-12 | 英诺湖医药(杭州)有限公司 | 抗pd-l1和4-1bb的双功能抗体及其医药用途 |
| WO2023180523A1 (fr) | 2022-03-24 | 2023-09-28 | Pieris Pharmaceuticals Gmbh | Procédé de purification de protéines de fusion |
| WO2024064713A1 (fr) * | 2022-09-21 | 2024-03-28 | Seagen Inc. | Nouvelle protéine de fusion spécifique à cd137 et cd228 |
| CN116211860B (zh) * | 2023-05-10 | 2023-08-22 | 细胞生态海河实验室 | Ck2抑制剂cx4945在制备肿瘤治疗中防止免疫细胞耗竭药物应用、抑制剂及联合物 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| JPH01215289A (ja) | 1988-02-22 | 1989-08-29 | Toa Nenryo Kogyo Kk | 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法 |
| FR2649991B2 (fr) | 1988-08-05 | 1994-03-04 | Rhone Poulenc Sante | Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| DK1136556T3 (da) | 1991-11-25 | 2005-10-03 | Enzon Inc | Fremgangsmåde til fremstilling af multivalente antigen-bindende proteiner |
| US5728553A (en) | 1992-09-23 | 1998-03-17 | Delta Biotechnology Limited | High purity albumin and method of producing |
| US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| US6080560A (en) | 1994-07-25 | 2000-06-27 | Monsanto Company | Method for producing antibodies in plant cells |
| US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| US6620413B1 (en) | 1995-12-27 | 2003-09-16 | Genentech, Inc. | OB protein-polymer chimeras |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| CA2233725A1 (fr) | 1998-03-31 | 1999-09-30 | Hemosol Inc. | Complexes d'amidon hydroxyethyles d'hemoglobine |
| AU767131B2 (en) | 1998-06-08 | 2003-10-30 | F. Hoffmann-La Roche Ag | Use of PEG-IFN-alpha and ribavirin for the treatment of chronic hepatitis C |
| US6403564B1 (en) | 1998-10-16 | 2002-06-11 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
| JP4336771B2 (ja) | 2001-03-09 | 2009-09-30 | モルフォシス アーゲー | 血清アルブミン結合部分 |
| AU2003275958A1 (en) | 2003-08-25 | 2005-03-10 | Pieris Proteolab Ag | Muteins of tear lipocalin |
| US7288638B2 (en) | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
| US7892827B2 (en) | 2004-11-26 | 2011-02-22 | Pieris Ag | Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4) |
| CA2622441A1 (fr) | 2005-09-27 | 2007-04-05 | Amunix, Inc. | Produits pharmaceutiques proteiques et utilisations de ceux-ci |
| AU2015205530B8 (en) * | 2014-01-13 | 2019-09-19 | Pieris Pharmaceuticals Gmbh | Multi-specific polypeptide useful for localized tumor immunomodulation |
| CN114316067A (zh) * | 2015-05-04 | 2022-04-12 | 皮里斯制药有限公司 | 抗癌融合多肽 |
| SG11201708339QA (en) * | 2015-05-04 | 2017-11-29 | Pieris Pharmaceuticals Gmbh | Proteins specific for cd137 |
| RU2754466C2 (ru) * | 2015-05-18 | 2021-09-02 | ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ | Слитый полипептид с противораковой активностью |
| BR112018013677A2 (pt) * | 2016-01-11 | 2019-01-22 | Inhibrx Inc | proteínas de fusão de ligação de 41bb multivalentes e multiespecíficas |
| MX2017016851A (es) * | 2016-03-04 | 2018-04-30 | Sichuan Kelun Biotech Biopharmaceutical Co Ltd | Anticuerpo para el ligando del factor 1 de muerte celular programada (pdl-1), composicion farmaceutica del mismo y uso de los mismos. |
| CN113773387B (zh) * | 2016-06-13 | 2024-06-21 | 天境生物科技(上海)有限公司 | Pd-l1抗体及其用途 |
| WO2018087108A1 (fr) * | 2016-11-09 | 2018-05-17 | Pieris Pharmaceuticals Gmbh | Protéines spécifiques de cd137 |
| CN107082812B (zh) * | 2017-03-29 | 2018-11-13 | 上海科医联创生物科技有限公司 | 一种恢复衰竭性免疫细胞功能的融合蛋白及其应用 |
| US11421029B2 (en) * | 2017-09-01 | 2022-08-23 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Recombinant bispecific antibodies to PD-L1 and CTLA-4 |
| WO2023000675A1 (fr) * | 2021-07-23 | 2023-01-26 | 安徽安科生物工程（集团）股份有限公司 | Anticorps bispécifique ciblant pd-l1 et 4-1bb |
-
2019
- 2019-07-31 KR KR1020217006003A patent/KR20210040103A/ko unknown
- 2019-07-31 JP JP2021529519A patent/JP7482488B2/ja active Active
- 2019-07-31 HR HRP20230590TT patent/HRP20230590T2/hr unknown
- 2019-07-31 AU AU2019315703A patent/AU2019315703A1/en active Pending
- 2019-07-31 MX MX2021000401A patent/MX2021000401A/es unknown
- 2019-07-31 CA CA3100119A patent/CA3100119A1/fr active Pending
- 2019-07-31 ES ES19746089T patent/ES2948717T3/es active Active
- 2019-07-31 SI SI201930558T patent/SI3830120T1/sl unknown
- 2019-07-31 EP EP23167877.2A patent/EP4249064A3/fr active Pending
- 2019-07-31 FI FIEP19746089.2T patent/FI3830120T3/fi active
- 2019-07-31 CN CN201980050587.8A patent/CN112789292A/zh active Pending
- 2019-07-31 LT LTEPPCT/EP2019/070596T patent/LT3830120T/lt unknown
- 2019-07-31 MD MDE20210513T patent/MD3830120T3/ro unknown
- 2019-07-31 WO PCT/EP2019/070596 patent/WO2020025659A1/fr active Application Filing
- 2019-07-31 HU HUE19746089A patent/HUE062320T2/hu unknown
- 2019-07-31 BR BR112020025263-8A patent/BR112020025263A2/pt unknown
- 2019-07-31 US US17/264,080 patent/US20210363257A1/en active Pending
- 2019-07-31 RS RS20230461A patent/RS64343B9/sr unknown
- 2019-07-31 EP EP19746089.2A patent/EP3830120B9/fr active Active
- 2019-07-31 TW TW108127283A patent/TWI837156B/zh active
- 2019-07-31 DK DK19746089.2T patent/DK3830120T3/da active
- 2019-07-31 PL PL19746089.2T patent/PL3830120T3/pl unknown
- 2019-07-31 SG SG11202100989UA patent/SG11202100989UA/en unknown
-
2020
- 2020-12-17 IL IL279541A patent/IL279541A/en unknown
-
2021
- 2021-01-01 PH PH12021550001A patent/PH12021550001A1/en unknown
- 2021-01-07 ZA ZA2021/00125A patent/ZA202100125B/en unknown
- 2021-01-26 CL CL2021000207A patent/CL2021000207A1/es unknown
-
2023
- 2023-06-29 CY CY20231100305T patent/CY1126148T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1765872B1 (fr) | Immunoglobuline glycosylee et immunoadhesine la comprenant | |
| US20240067757A1 (en) | COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc CONSTRUCTS | |
| JP2018526989A5 (fr) | ||
| JP2018519803A5 (fr) | ||
| JP2018515085A5 (fr) | ||
| US11505595B2 (en) | TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15RA Fc-fusion proteins and TIM-3 antigen binding domains | |
| CA2778864C (fr) | Anticorps humanises contre il-22ra humain | |
| CN110234355B (zh) | 单体人IgG1 Fc和双特异性抗体 | |
| JP7366056B2 (ja) | ＩＬ－１５／ＩＬ－１５ＲＡ Ｆｃ融合タンパク質およびＬＡＧ－３抗原結合ドメインを含む、ＬＡＧ－３を標的とするヘテロ二量体融合タンパク質 | |
| JP2022503959A (ja) | Ｉｌ－１２ヘテロ二量体ｆｃ－融合タンパク質 | |
| FI3830120T3 (fi) | CD137:lle ja PD-L1:lle spesifinen uusi fuusioproteiini | |
| AU2018269585B2 (en) | BTLA agonist antibodies and uses thereof | |
| EP3833391A1 (fr) | PROTÉINES CHIMÈRES CIBLÉES SUR SIRP1alpha ET LEURS UTILISATIONS | |
| KR102602539B1 (ko) | Fc-융합 고친화성 IgE 수용체 알파 사슬 | |
| JPWO2020025659A5 (fr) | ||
| US20220119472A1 (en) | Modulation of dendritic cell lineages | |
| JPWO2020173897A5 (fr) | ||
| JP2023549150A (ja) | 抗ヒト胸腺間質性リンパ球新生因子抗体及びその製造方法と使用 | |
| CA3204723A1 (fr) | Fusions de polypeptides d'interleukine-10 mutants avec des molecules de liaison a l'antigene pour moduler la fonction de cellules immunitaires | |
| RU2020139055A (ru) | Новый слитый белок, специфичный для cd137 и pd-l1 | |
| RU2819097C2 (ru) | Il-12 гетеродимерные слитые белки fc | |
| WO2024046301A1 (fr) | Protéine de fusion comprenant un polypeptide taci et son utilisation |